clinical trial · NCT06198907
Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences·phase2·not yet recruiting·n = 69
Non-Small-Cell Lung CancerGolidocitinibSintilimabplatinum doublet chemotherapy
brief summary
This is a phase 2 Study to investigate the safety, tolerability, and anti-tumor activity of golidocitinib in combination with sintilimab as the front-line treatment for patients with metastatic PD-L1 positive non-small cell lung cancer (NSCLC)
started
Jan 1, 2024
primary completion
Dec 1, 2026
completion
Dec 1, 2027
last updated
Jan 10, 2024
official title
A Phase 2, Open-label, Single Arm Study to Investigate the Safety and Efficiency of Golidocitinib in Combination With Sintilimab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With PD-L1TPS ≥ 1%)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol